Principal Investigator
Lynn Feun
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230430
Clinical Trial Summary
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647